Skip to main content
Theralase Technologies Inc. logo

Theralase Technologies Inc. — Investor Relations & Filings

Ticker · TLT ISIN · CA88337V1004 LEI · 529900NI3Y8GLE2IBF28 TSXV Manufacturing
Open in API
Filings indexed 698 across all filing types
Latest filing 2021-11-18 Regulatory Filings
Country CA Canada
Listing TSXV TLT

About Theralase Technologies Inc.

https://theralase.com/

Theralase Technologies Inc. designs, develops, manufactures, and markets patented laser technology platforms for both bio-stimulative and bio-destructive medical applications. The company operates two core divisions. The first is Cool Laser Therapy (CLT), which utilizes proprietary super-pulsed laser systems for therapeutic purposes, focusing on pain management, inflammation reduction, tissue repair, and the effective elimination of chronic knee pain. The second is Anti-Cancer Therapy (ACT), which employs patented light-activated Photo Dynamic Compounds (PDCs) combined with laser technology for destructive applications, specifically targeting the safe and effective destruction of cancer, bacteria, and viruses.

Recent filings

Filing Released Lang Actions
Other Correspondence.PDF
Regulatory Filings Classification · 100% confidence The document is a short notice from the Ontario Securities Commission regarding the withdrawal of a Final Shelf Prospectus dated June 28, 2021. It is very brief (446 characters) and does not contain any financial data or detailed report content. It is an official regulatory announcement about a filing status (withdrawal of a prospectus). According to the rules, such brief regulatory announcements that do not contain substantive report content should be classified as Regulatory Filings (RNS).
2021-11-18 English
News release - English.pdf
Regulatory Filings
2021-11-15 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification statement by the Interim CEO/COO regarding the interim financial report and interim MD&A for the period ended June 30, 2021. It references Form 52-109F2, which is a certification of disclosure in interim filings. The document does not contain actual financial data or substantive financial analysis but rather attests to the accuracy and fairness of the interim filings. It is a certification letter, not the interim report itself. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than as an Interim Report (IR). The document length is 3265 characters, which is relatively short and consistent with a certification letter rather than a full report.
2021-08-31 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109F2 Certification of Interim Filings by the CFO of Theralase Technologies Inc. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended June 30, 2021. The document is primarily an officer certification letter confirming the accuracy and completeness of the interim filings, including controls over financial reporting. It does not contain the actual interim financial statements or substantive financial data itself, but rather attests to their validity. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR) itself. The document length is 3226 characters, which is relatively short and consistent with a certification letter rather than a full report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-08-31 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Interim Consolidated Financial Statements - Unaudited As at June 30, 2021 and for the six-month period ended June 30, 2021 and 2020.' It contains detailed financial statements including Statements of Financial Position, Operations, Cash Flows, and Changes in Equity for the six-month period ended June 30, 2021, with comparative figures for 2020. The notes indicate compliance with IAS 34 'Interim Financial Reporting' and IFRS standards, confirming this is an interim financial report. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2021
2021-08-31 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Management's Discussion and Analysis of Financial Condition and Operations' (MD&A) and discusses the company's financial condition, operations, clinical studies, leadership changes, and forward-looking statements. It references unaudited condensed interim consolidated financial statements for the six-month period ended June 30, 2021, indicating it is related to a quarterly or interim period. The document contains substantive financial and operational analysis, not just an announcement or certification. It is not a full annual report (10-K), nor is it an earnings release (ER) which would be shorter and more summary-focused. It is not a call transcript, proxy statement, or other categories. The MD&A is a detailed management report explaining financial results and business trends for a period shorter than a full fiscal year, consistent with the definition of an Interim / Quarterly Report (IR). Therefore, the correct classification is IR with high confidence. H1 2021
2021-08-31 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.